StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.34+0.02 (+0.86%)

Close on Nov 18, 2026Market cap $138.28MP/E –Yield –

Protara Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Protara Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$66.13M. For fiscal 2025 it was -$56.37M. The highest annual figure on record is -$5.01M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$56.37M–
FY2024Dec 31, 2024-$35.81M–
FY2023Dec 31, 2023-$37.56M–
FY2022Dec 31, 2022-$26.46M–
FY2021Dec 31, 2021-$34.50M–
FY2020Dec 31, 2020-$23.41M–
FY2019Dec 31, 2019-$5.01M–
FY2018Dec 31, 2018-$23.23M–
FY2017Dec 31, 2017-$22.35M–
FY2016Dec 31, 2016-$23.69M–
FY2015Dec 31, 2015-$17.57M–
FY2014Dec 31, 2014-$9.99M–
FY2013Dec 31, 2013-$6.66M–
FY2012Dec 31, 2012-$8.23M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.39M–
Q1 FY2026Mar 31, 2026-$21.34M–
Q4 FY2025Dec 31, 2025-$16.95M–
Q3 FY2025Sep 30, 2025-$12.45M–
Q2 FY2025Jun 30, 2025-$12.25M–
Q1 FY2025Mar 31, 2025-$14.71M–
Q4 FY2024Dec 31, 2024-$9.31M–
Q3 FY2024Sep 30, 2024-$8.43M–
Q2 FY2024Jun 30, 2024-$7.69M–
Q1 FY2024Mar 31, 2024-$10.38M–
Q4 FY2023Dec 31, 2023-$8.70M–
Q3 FY2023Sep 30, 2023-$6.56M–
Q2 FY2023Jun 30, 2023-$9.41M–
Q1 FY2023Mar 31, 2023-$12.89M–
Q4 FY2022Dec 31, 2022-$5.03M–
Q3 FY2022Sep 30, 2022-$5.35M–
Q2 FY2022Jun 30, 2022-$5.12M–
Q1 FY2022Mar 31, 2022-$10.96M–
Q4 FY2021Dec 31, 2021-$6.91M–
Q3 FY2021Sep 30, 2021-$6.20M–
Q2 FY2021Jun 30, 2021-$9.47M–
Q1 FY2021Mar 31, 2021-$11.92M–
Q4 FY2020Dec 31, 2020-$6.77M–
Q3 FY2020Sep 30, 2020-$3.76M–
Q2 FY2020Jun 30, 2020-$5.73M–
Q1 FY2020Mar 31, 2020-$7.15M–
Q4 FY2019Dec 31, 2019-$1.09M–
Q3 FY2019Sep 30, 2019-$1.21M–
Q2 FY2019Jun 30, 2019-$1.30M–
Q1 FY2019Mar 31, 2019-$1.41M–
Q4 FY2018Dec 31, 2018-$4.31M–
Q3 FY2018Sep 30, 2018-$3.12M–
Q2 FY2018Jun 30, 2018-$10.35M–
Q1 FY2018Mar 31, 2018-$5.46M–
Q4 FY2017Dec 31, 2017-$5.70M–
Q3 FY2017Sep 30, 2017-$5.93M–
Q2 FY2017Jun 30, 2017-$3.28M–
Q1 FY2017Mar 31, 2017-$7.45M–
Q4 FY2016Dec 31, 2016-$5.58M–
Q3 FY2016Sep 30, 2016-$6.65M–

More Protara Therapeutics figures

See a number that looks wrong?